Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unresectable Pancreatic Carcinoma × tocilizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 12 Lymphoma, Non-Hodgkin 9 Arthritis, Rheumatoid 7 Carcinoma, Non-Small-Cell Lung 6 Breast Neoplasms 6 Recurrence 4 Neoplasms 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, B-Cell 4 Lymphoma 4 Leukemia, Myeloid, Acute 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Ovarian Neoplasms 3 Colorectal Neoplasms 3 Urinary Bladder Neoplasms 2 Solid Tumors 2 Respiratory Distress Syndrome 2 Pancreatic Neoplasms 2 Myelodysplastic Syndromes 2 Lymphoma, Mantle-Cell 2 Lymphoma, Follicular 2 Leukemia 2 Hematologic Neoplasms 2 Fallopian Tube Neoplasms 2 Cytokine Release Syndrome 2 Craniopharyngioma 2 Carcinoma, Hepatocellular 2 COVID-19 2

Interventions

tocilizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02767557 2023-09-22

PACTO

Herlev Hospital

Phase 2 Completed

Gastrointestinal

Unresectable Pancreatic Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡